COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
To provide antibodies, compounds, pharmaceutical compositions and methods for treating immune-mediated diseases such as Alzheimer's disease or tauopathy diseases.SOLUTION: Provided herein is an antibody that binds to human IL-34, where the antibody comprises a heavy chain variable region (VH) a...
Saved in:
Main Authors | , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English Japanese |
Published |
16.05.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To provide antibodies, compounds, pharmaceutical compositions and methods for treating immune-mediated diseases such as Alzheimer's disease or tauopathy diseases.SOLUTION: Provided herein is an antibody that binds to human IL-34, where the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprises a heavy chain complementarity determining region (HCDR) HCDR1, HCDR2 and HCDR3, and the VL comprises a light chain complementarity determining region (LCDR) LCDR1, LCDR2 and LCDR3. Also provided is an agent for treating an immune-mediated disease selected from the group consisting of Alzheimer's disease, a tauopathy disease, Sjogren syndrome (SS), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), atopic dermatitis, kidney diseases, sepsis, and/or non-alcoholic fatty liver disease (NAFLD).SELECTED DRAWING: None
【課題】アルツハイマー病又はタウオパチー疾患などの免疫介在性疾患を治療するための抗体、化合物、医薬組成物及び方法を提供する。【解決手段】ヒトIL-34に結合する抗体であって、前記抗体が、重鎖可変領域(VH)と、軽鎖可変領域(VL)と、を含み、前記VHが、重鎖相補性決定領域(HCDR)HCDR1、HCDR2、及びHCDR3を含み、前記VLが、軽鎖相補性決定領域(LCDR)LCDR1、LCDR2、及びLCDR3を含む、抗体を提供する。また、前記抗体を含む、アルツハイマー病、タウオパチー病、シェーグレン症候群(SS)、関節リウマチ(RA)、炎症性腸疾患(IBD)、アトピー性皮膚炎、腎疾患、敗血症、及び/又は非アルコール性脂肪性肝疾患(NAFLD)からなる群から選択される免疫介在性疾患の治療剤を提供する。【選択図】なし |
---|---|
AbstractList | To provide antibodies, compounds, pharmaceutical compositions and methods for treating immune-mediated diseases such as Alzheimer's disease or tauopathy diseases.SOLUTION: Provided herein is an antibody that binds to human IL-34, where the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprises a heavy chain complementarity determining region (HCDR) HCDR1, HCDR2 and HCDR3, and the VL comprises a light chain complementarity determining region (LCDR) LCDR1, LCDR2 and LCDR3. Also provided is an agent for treating an immune-mediated disease selected from the group consisting of Alzheimer's disease, a tauopathy disease, Sjogren syndrome (SS), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), atopic dermatitis, kidney diseases, sepsis, and/or non-alcoholic fatty liver disease (NAFLD).SELECTED DRAWING: None
【課題】アルツハイマー病又はタウオパチー疾患などの免疫介在性疾患を治療するための抗体、化合物、医薬組成物及び方法を提供する。【解決手段】ヒトIL-34に結合する抗体であって、前記抗体が、重鎖可変領域(VH)と、軽鎖可変領域(VL)と、を含み、前記VHが、重鎖相補性決定領域(HCDR)HCDR1、HCDR2、及びHCDR3を含み、前記VLが、軽鎖相補性決定領域(LCDR)LCDR1、LCDR2、及びLCDR3を含む、抗体を提供する。また、前記抗体を含む、アルツハイマー病、タウオパチー病、シェーグレン症候群(SS)、関節リウマチ(RA)、炎症性腸疾患(IBD)、アトピー性皮膚炎、腎疾患、敗血症、及び/又は非アルコール性脂肪性肝疾患(NAFLD)からなる群から選択される免疫介在性疾患の治療剤を提供する。【選択図】なし |
Author | MEGAN BRITTANY LANNAN ELIZABETH ANNE WEST MARCIO CHEDID ANDREW DIXON SKORA ADAM S FLEISHER MARK MINTUN ROBIN ELIZABETH WALSH YE MING SARAH ELISABETH RAINES ALBERT LO VICTOR H OBUNGU JOHN RANDALL SIMS II |
Author_xml | – fullname: ANDREW DIXON SKORA – fullname: YE MING – fullname: ADAM S FLEISHER – fullname: ALBERT LO – fullname: SARAH ELISABETH RAINES – fullname: ROBIN ELIZABETH WALSH – fullname: MARK MINTUN – fullname: ELIZABETH ANNE WEST – fullname: MARCIO CHEDID – fullname: MEGAN BRITTANY LANNAN – fullname: VICTOR H OBUNGU – fullname: JOHN RANDALL SIMS II |
BookMark | eNrjYmDJy89L5WTQc_b3DfAP9XMJVnD0c1HwdQ3x8AeyQxyD3F1DPP3cFTz9QlyDfFxDvT39dI1NeBhY0xJzilN5oTQ3g5Kba4izh25qQX58anFBYnJqXmpJvFeAkYGRsYGZuYWxkaMxUYoAJwgn6w |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | インターロイキン-34を標的とする化合物及び方法 |
ExternalDocumentID | JP2023067832A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_JP2023067832A3 |
IEDL.DBID | EVB |
IngestDate | Fri Oct 04 04:55:45 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English Japanese |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_JP2023067832A3 |
Notes | Application Number: JP20220172479 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230516&DB=EPODOC&CC=JP&NR=2023067832A |
ParticipantIDs | epo_espacenet_JP2023067832A |
PublicationCentury | 2000 |
PublicationDate | 20230516 |
PublicationDateYYYYMMDD | 2023-05-16 |
PublicationDate_xml | – month: 05 year: 2023 text: 20230516 day: 16 |
PublicationDecade | 2020 |
PublicationYear | 2023 |
RelatedCompanies | ELI LILLY & CO |
RelatedCompanies_xml | – name: ELI LILLY & CO |
Score | 3.6031113 |
Snippet | To provide antibodies, compounds, pharmaceutical compositions and methods for treating immune-mediated diseases such as Alzheimer's disease or tauopathy... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
Title | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230516&DB=EPODOC&locale=&CC=JP&NR=2023067832A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8Mw8JhT1DedijqVItK3KG3TdXsosjXt5rAfzFb2NpYtARV0uIp_30vsdE97u-Tg8gH3lcvdAdxwbrVVtzoiHEEJanxKUAkKQj0puSuEN9ft3uKkNSjocOyOa_C2yoXRdUK_dXFE5KgZ8nup5fXi_xGL6b-Vyzv-glMf91HuM7PyjtGedq2WyXp-mKUsDcwg8IeZmYx-cSiYHbu7BdvKjlaF9sPnnkpLWazrlOgAdjIk914eQu112oC9YNV6rQG7cRXxRrBivuUR3AZpnKVFwp6MbsKMOMwHKcJ5d9QP84ekb-jyto9hgR45cegxXEdhHgwILjz5O-ZkmK1t0jmBOvr_4hQMz6XetN2RvG1NKeUzLm05l_ZMirndkRY9g-YGQucbsU3YVyMVDrdaF1AvP7_EJWrZkl_p2_kBqK18Bg |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8JADG8QjfimqEHxYzFmb9NsuzF4WMzYBmPuKzgMbwsHd4maKJEZ_327cyhPvDXXpPeRtL3f9doC3FKqdstudQrTGVHQ4xMFnSBTiMk5NRgzF6LdWxR3_AkJpsa0Bm_rXBhRJ_RbFEdEjZqjvhfCXi__H7Fc8bdydU9fcOjjYZBZrlyhY7xPG2pHdvuWlyZu4siOYwWpHI9_eWiYdc3egV0TMaHASs_9Mi1luelTBoewl6K49-IIaq-zJjScdeu1JuxHVcQbyUr5Vsdw5yRRmkxi90myY1eKvMxPkM7s8dDLRvFQEuVtQ2-CiFzRyQncDLzM8RWcOP_bZh6kG4vUT6GO-J-1QDINYs66PU676owQOqdc4wuuzTlbaD2ukjNobxF0vpV7DQ0_i8I8HMWPbTgoOWVoXO1cQL34_GKX6HELeiVO6geaB37w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=COMPOUNDS+AND+METHODS+TARGETING+INTERLEUKIN-34&rft.inventor=ANDREW+DIXON+SKORA&rft.inventor=YE+MING&rft.inventor=ADAM+S+FLEISHER&rft.inventor=ALBERT+LO&rft.inventor=SARAH+ELISABETH+RAINES&rft.inventor=ROBIN+ELIZABETH+WALSH&rft.inventor=MARK+MINTUN&rft.inventor=ELIZABETH+ANNE+WEST&rft.inventor=MARCIO+CHEDID&rft.inventor=MEGAN+BRITTANY+LANNAN&rft.inventor=VICTOR+H+OBUNGU&rft.inventor=JOHN+RANDALL+SIMS+II&rft.date=2023-05-16&rft.externalDBID=A&rft.externalDocID=JP2023067832A |